{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:50:06Z","timestamp":1792709406220,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"DOI":"10.7759\/cureus.68419","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:18:45Z","timestamp":1725257925000},"source":"Crossref","is-referenced-by-count":13,"title":["Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies"],"prefix":"10.7759","author":[{"given":"Sameenkhan","family":"Anwarkhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jebastin","family":"Koilpillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodharan","family":"Narayanasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge WM","year":"2007","unstructured":"Pardridge WM. Drug targeting to the brain. Pharm Res. 2007, 24:1733-44. 10.1007\/s11095-007-9324-2","journal-title":"Pharm Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1387\/ijdb.103224sl","article-title":"Current concepts of blood-brain barrier development","volume":"55","author":"Liebner S","year":"2011","unstructured":"Liebner S, Czupalla CJ, Wolburg H. Current concepts of blood-brain barrier development. Int J Dev Biol. 2011, 55:467-76. 10.1387\/ijdb.103224sl","journal-title":"Int J Dev Biol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-013-9608-0","article-title":"Blood-brain barrier structure and function and the challenges for CNS drug delivery","volume":"36","author":"Abbott NJ","year":"2013","unstructured":"Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013, 36:437-49. 10.1007\/s10545-013-9608-0","journal-title":"J Inherit Metab Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2008.07.003","article-title":"A perivascular origin for mesenchymal stem cells in multiple human organs","volume":"3","author":"Crisan M","year":"2008","unstructured":"Crisan M, Yap S, Casteilla L, et al.. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008, 3:301-13. 10.1016\/j.stem.2008.07.003","journal-title":"Cell Stem Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00624","article-title":"Macromolecular drug carriers for targeted glioblastoma therapy: preclinical studies, challenges, and future perspectives","volume":"8","author":"Raucher D","year":"2018","unstructured":"Raucher D, Dragojevic S, Ryu J. Macromolecular drug carriers for targeted glioblastoma therapy: preclinical studies, challenges, and future perspectives. Front Oncol. 2018, 8:624. 10.3389\/fonc.2018.00624","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the blood-brain barrier: challenges and tricks for CNS drug delivery","volume":"87","author":"Bors L","year":"2019","unstructured":"Bors L, Erd\u0151 F. Overcoming the blood-brain barrier: challenges and tricks for CNS drug delivery. Sci Pharm. 2019, 87:6. 10.3390\/scipharm87010006","journal-title":"Sci Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1119-z","article-title":"Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research","volume":"30","author":"Passeleu-Le Bourdonnec C","year":"2013","unstructured":"Passeleu-Le Bourdonnec C, Carrupt PA, Scherrmann JM, Martel S. Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research. Pharm Res. 2013, 30:2729-56. 10.1007\/s11095-013-1119-z","journal-title":"Pharm Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira A","year":"2012","unstructured":"Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012, 19:1946-2025. 10.2174\/092986712800167392","journal-title":"Curr Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cells7040024","article-title":"Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective","volume":"7","author":"He Q","year":"2018","unstructured":"He Q, Liu J, Liang J, et al.. Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective. Cells. 2018, 7:24. 10.3390\/cells7040024","journal-title":"Cells"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh DS","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts N, et al.. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des. 2016, 22:1177-93. 10.2174\/1381612822666151221150733","journal-title":"Curr Pharm Des"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.05.015","article-title":"Novel Curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates","volume":"526","author":"Barbara R","year":"2017","unstructured":"Barbara R, Belletti D, Pederzoli F, et al.. Novel Curcumin loaded nanoparticles engineered for blood-brain barrier crossing and able to disrupt Abeta aggregates. Int J Pharm. 2017, 526:413-24. 10.1016\/j.ijpharm.2017.05.015","journal-title":"Int J Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60293-y","article-title":"Delivering crocetin across the blood-brain barrier by using \u03b3-cyclodextrin to treat Alzheimer's disease","volume":"10","author":"Wong KH","year":"2020","unstructured":"Wong KH, Xie Y, Huang X, et al.. Delivering crocetin across the blood-brain barrier by using \u03b3-cyclodextrin to treat Alzheimer's disease. Sci Rep. 2020, 10:3654. 10.1038\/s41598-020-60293-y","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00137-X","article-title":"Increased expression of bioactive chemokines in human cerebromicrovascular endothelial cells and astrocytes subjected to simulated ischemia in vitro","volume":"101","author":"Zhang W","year":"1999","unstructured":"Zhang W, Smith C, Shapiro A, Monette R, Hutchison J, Stanimirovic D. Increased expression of bioactive chemokines in human cerebromicrovascular endothelial cells and astrocytes subjected to simulated ischemia in vitro. J Neuroimmunol. 1999, 101:148-60. 10.1016\/S0165-5728(99)00137-X","journal-title":"J Neuroimmunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.2.262","article-title":"Aquaporin-4 expression is increased in oedematous human brain tumours","volume":"72","author":"Saadoun S","year":"2002","unstructured":"Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA. Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry. 2002, 72:262-5. 10.1136\/jnnp.72.2.262","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310160","article-title":"Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures","volume":"15","author":"Huang MB","year":"1999","unstructured":"Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS Res Hum Retroviruses. 1999, 15:1265-77. 10.1089\/088922299310160","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3233\/DMA-2009-0602","article-title":"Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis","volume":"26","author":"Ortiz GG","year":"2009","unstructured":"Ortiz GG, Mac\u00edas-Islas MA, Pacheco-Mois\u00e9s FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers. 2009, 26:35-9. 10.3233\/DMA-2009-0602","journal-title":"Dis Markers"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry H","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020, 17:69. 10.1186\/s12987-020-00230-3","journal-title":"Fluids Barriers CNS"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b04855","article-title":"Bridging bio-nano science and cancer nanomedicine","volume":"11","author":"Bj\u00f6rnmalm M","year":"2017","unstructured":"Bj\u00f6rnmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Bridging bio-nano science and cancer nanomedicine. ACS Nano. 2017, 11:9594-613. 10.1021\/acsnano.7b04855","journal-title":"ACS Nano"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0136-y","article-title":"Nanoparticle based insulin delivery system: the next generation efficient therapy for type 1 diabetes","volume":"13","author":"Sharma G","year":"2015","unstructured":"Sharma G, Sharma AR, Nam JS, Doss GP, Lee SS, Chakraborty C. Nanoparticle based insulin delivery system: the next generation efficient therapy for type 1 diabetes. J Nanobiotechnology. 2015, 13:74. 10.1186\/s12951-015-0136-y","journal-title":"J Nanobiotechnology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-006-9025-3","article-title":"Blood-brain barrier: structural components and function under physiologic and pathologic conditions","volume":"1","author":"Persidsky Y","year":"2006","unstructured":"Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006, 1:223-36. 10.1007\/s11481-006-9025-3","journal-title":"J Neuroimmune Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276816-utilizing-multifaceted-approaches-to-target-drug-delivery-in-the-brain-from-nanoparticles-to-biological-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:18:49Z","timestamp":1725257929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276816-utilizing-multifaceted-approaches-to-target-drug-delivery-in-the-brain-from-nanoparticles-to-biological-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.68419","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}